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Introduction. Among cardiovascular diseases with an important impact on the general 
population, hypertension (HTA) is also found. Considering the association of HTA with risk 
factors such as diabetes and the level of impact on public health spending, the European Society 
of Hypertension has developed a guide to the evaluation and treatment of hypertension and 
associated diseases. Starting from the idea that atherosclerosis is the most common cause of 
hypertension and that at the base of the pathophysiology of atherosclerosis is the dyslipidemic 
process, and following dietary habits with excess fat and often consumption excess alcohol, 
accompanied by smoke and lesser movement and all of these are spreading to younger age, we 
have given greater interest to these findings. 
Aim of the study. To identify the risk factors and their influence on hypertension in a group of 
100 patients over the two years. 
Materials and methods. The work was based on the random incorporation of displaced patients 
from the Public Health Care Institution Institute of Cardiology from Chisinau after the screening 
of more than 200 clinical observation sheets. 
Results. We calculated the mean value of cholesterol, LDL-C, HDL-C, triglycerides and each of 
these were reported based on glucose, blood pressure, body mass index, smokers, personal 
history of early cardiopathy, and their dispersion according to the age in order to be able to 
capture the maximum incidence and to appreciate the extent to which new behavioral 
movements (increased smoking among women) have a consequence, and depending on the 
background of the sick, knowing that in rural areas the diet is richer in animal fat, but physical 
effort is more engaging, while in urban areas food often becomes hypercaloric compared to the 
lower level of exercise. We compared dynamically, the evolution of clinical symptoms, the value 
of laboratory and imaging results, and the relation to smoking, respectively the body mass index, 
as well as the measurement of their results in the number of coronary events. 
Conclusion. Metabolic syndrome includes symptoms related to a hyperactivity of the 
sympathetic system, with hypertension being the most important of these disorders, but also 
obesity, insulin resistance, glucose intolerance, and blood lipid abnormalities. According to the 
analysis of predisposing factors in the occurrence of metabolic syndrome-induced HTA, 
dyslipidemia was the most common risk factor (87,6%), obesity was 66%, smoking at 58,0%, 
and hyperglycemia at 51,6%. Basic treatment includes inhibitors of the angiotensin converting 
enzyme, β-blockers, angiotensin receptor blockers (sartans), antidiabetic agents, platelet 
antiaggregants and hypolipemics. 
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Introduction. HIV produces a chronic, progressive and irreversible infection, altering the host 
defense mechanisms, installing AIDS and opportunistic infections, with invariable progression to 
death, in absence of treatment. HIV infection rapidly affects young and fertile people, who are 
receptive to injectable drugs use, and practicing unprotected sexual intercourse that favors the 
spread of the epidemic. AIDS is a global epidemic with about 40 million infected people. 
Twenty million people have died since the early 1980s because of AIDS-related complications. 
Every ten seconds, in the world, a person dies of AIDS. According to WHO, the most common 
cause of women's mortality worldwide is AIDS. 50% of newly infected people are aged between 
15 and 25 years. At the end of 2016, 11.043 HIV-infected were registered in Moldova, and 
during the first nine months of 2017, 614 patients were newly diagnosed. The estimated number 
of all bearers is about 15 thousand citizens of Moldova. 
Case report. Patient M., 31 years, driver, was hospitalized with the diagnosis of HIV and many 
coinfections: chronic viral hepatitis B, toxic hepatitis, ascites, chronic pancreatitis, and chronic 
cholecystitis. Clinical picture: general weakness, periodic pronounced pain in the right side of 
abdomen, loss of appetite, nausea, and asthenia.  Period of hospitalization: 27 days. The 
diagnosis was confirmed in 2009, the route of infection was sexual, but the patient also used 
injectable drugs. During the hospitalization he received antiretroviral treatment: Darunavir 600 
mg once a day, Ritonavir 600 mg twice a day, Tenofovir + Lamivudine 1x1, and symptomatic: 
Mezym, Verospiron, Panangin, Furosemide, Hepasol, Sorbilact, Infusol, Hemodez, Lipesol, 
Arginine. The patient was discharged with the recommendation to be under the supervision of 
the infectious disease doctor, and to continue the antiretroviral and symptomatic treatment, 
repeated control over 3 months. 
Conclusions. HIV / AIDS is a chronic, lifelong disease without known healing, and infected 
people have to be medically monitored for the rest of their lives. Antiretroviral therapy aims to 
prolong lifetime duration and improve the quality of life of patients.  
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Introduction. The fixed dose combined pharmaceutical medicine represent an association of 
two or more drug substances, using in several branches, including the hypopotassemia treatment 
(potassium concentration in the blood plasma is below 3.5 mmol/l). For example: Panangin, 
Asparcam, Antikircel. The single-component therapy with potassium chloride, potassium iodide 
or other potassium salts ensures the essential pharmaco-therapeutic in up to 50% of the medical 
treatment cases, therefore it is less effective, than using of combined pharmaceutical medicine, 
that shows better results in hypopotassemia. In particular, those combinations of pharmaceutical 
substances are plausible which achieve not only the removal of the hypopotassemia symptoms 
(cramps, cardiac arrhythmias), but also the causal treatment. 
Aim of the study. Evaluation of the combined pharmaceutical products market used in 
hypopotassemia in the Republic of Moldova (RM). 
